These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 233105)

  • 1. [Mechanism of platelet aggregation inhibition].
    Abiko Y; Ashida S
    Rinsho Byori; 1979; Suppl 40():169-80. PubMed ID: 233105
    [No Abstract]   [Full Text] [Related]  

  • 2. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
    Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
    Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of platelet aggregation by a new agent, Ticlopidine.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium inhibits adenylate cyclase of human platelets.
    Imandt L; Tijhuis D; Wessels H; Haanen C
    Thromb Haemost; 1981 Apr; 45(2):142-5. PubMed ID: 6266068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Status and trends in the field of inhibitors of thrombocyte function].
    Glusa E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):575-9. PubMed ID: 6083929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of phospholipase activity in platelets.
    Lapetina EG; Schmitges CJ; Chandrabose K; Cuatrecasas P
    Adv Prostaglandin Thromboxane Res; 1978; 3():127-35. PubMed ID: 207172
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors.
    Asano T; Ochiai Y; Hidaka H
    Mol Pharmacol; 1977 May; 13(3):400-6. PubMed ID: 195193
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.
    Hagiwara M; Endo T; Kanayama T; Hidaka H
    J Pharmacol Exp Ther; 1984 Feb; 228(2):467-71. PubMed ID: 6141286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets.
    Lee H; Paton RC; Ruan C; Caen JP
    Thromb Haemost; 1981 Oct; 46(3):590-2. PubMed ID: 6797089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E1 and platelets.
    Bousser MG
    Biomedicine; 1973 Mar; 18(2):95-102. PubMed ID: 4354464
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of CI-930, a novel phosphodiesterase III inhibitor, on platelet aggregation and arachidonic acid metabolism.
    Chen XS; Zeng HW; Jiang YY; Wan WQ; Long K
    Zhongguo Yao Li Xue Bao; 1990 Jul; 11(4):338-43. PubMed ID: 1966575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulators of cyclic AMP systems.
    Hess SM; Chasin M; Free CA; Harris DN
    Adv Biochem Psychopharmacol; 1975; (14):153-67. PubMed ID: 242200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Present status and prospects of platelet inhibitors].
    Yasunaga K
    Rinsho Ketsueki; 1976 Jun; 17(6):590-9. PubMed ID: 184313
    [No Abstract]   [Full Text] [Related]  

  • 18. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
    Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of adenylate cyclase and the mechanism controlling platelet aggregation].
    Yoshida N; Aoki N
    Rinsho Byori; 1979; Suppl 40():47-53. PubMed ID: 233107
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.